Bibliography
- Vallet S, Witzens-Harig M, Jaeger D, Podar K. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opin Pharmacother 2012;13:473-94
- Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83:1583-1590
- Ito T, Ando H, Suzuki T, Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-50
- Zhu YX, Braggio E, Shi CX, Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9
- Papp K, Hu A, Day RM. Oral apremilast is active in the treatment of moderate to severe plaque psoriasis: results from a phase 2b, randomized, controlled study (PSOR-005) [poster 273]. Annual Meeting of the European Society for Dermatological Research 2011; 7 – 12 September 2011; Barcelona, Spain
- Schett G, Wollenhaupt J, Papp K, Apremilast is active in the treatment of psoriatic arthritis (PsA) [abstract]. Arthritis Rheum 2009;60(Suppl 10):1258